A huge investment of 43 billion dollars for cancer treatment from Pfizer!
Pfizer Inc, the US pharmaceutical company that produces coronavirus vaccines together with BioNTech, has made a $43 billion acquisition to expand its cancer treatment portfolio.
US-based pharmaceutical manufacturer Pfizer Inc signed a $43 billion acquisition deal.
The company acquired Seagen Inc for approximately $43 billion to expand its cancer treatment portfolio.
According to the news in AFP, Pfizer will pay $229 in cash per share as part of the purchase.
According to the same news, Pfizer bought Seagen's shares at a 32.7% premium as of Friday's close. This acquisition was recorded as the second largest investment in the company's history.
With the latest deal, Pfizer has added four approved cancer treatments to its portfolio. Cancer treatments added to the company's portfolio had reached sales of approximately $2 billion in 2022.
